A combined metabolic research peptide system designed for interaction and comparison studies

CagriReta 40 mg from SEMPICA HEALTHCARE is a pre-mixed research blend, supplied as a sealed pen containing two well-studied peptide compounds in a fixed and clearly defined composition. It is intended solely for research and development work and is supplied without instructions, protocols, or guidance of any kind.

This product is not a medicine, not a treatment, and not intended for human or animal use. By purchasing, you accept full responsibility for how it is stored, handled, and used within your own research setting.

What CagriReta 40 mg Contains

CagriReta 40 mg is composed of:

• Retatrutide – 30 mg
• Cagrilinitide – 10 mg

This combination is used in research to study how multiple metabolic signalling systems behave together, rather than examining each compound independently. In simple terms, it allows researchers to observe overlap, interaction, and timing differences between signalling pathways within the same experimental environment.

Why This Combination Is of Research Interest

Retatrutide and Cagrilinitide have each been the subject of extensive metabolic research. Retatrutide is studied for its broad, multi-pathway signalling activity, while Cagrilinitide is examined for its long-acting signalling behaviour.

When combined, researchers are able to explore questions such as:

• How extended signalling influences broader pathway activity
• Whether combined compounds alter signal duration or intensity
• How multi-pathway peptides behave when paired with long-acting analogues
• Differences between single-compound and blended research systems

This type of research is focused on understanding mechanisms, not producing outcomes.

Research Background and Reported Findings

Both compounds included in CagriReta have appeared in high-profile metabolic and weight-related research, with published studies reporting exceptionally strong results, including average body-weight reductions in the region of 20% or more in study participants over extended periods.

These reported findings are widely discussed in academic literature and explain why blended systems like CagriReta attract strong research attention.

It is important to be clear:

• These results come from external studies
• They are not linked to this product
• No outcomes are promised or implied
• This product is not sold for weight loss or treatment

Why a 40 mg Format Is Used

The 40 mg CagriReta format is commonly chosen for:

• Combination-based signalling research
• Comparative studies against higher-content blends
• Medium-duration observation work
• Researchers exploring interaction before scaling up

It provides a balanced research quantity without moving straight to higher total peptide loads.

How This Product Is Supplied

SEMPICA HEALTHCARE supplies CagriReta 40 mg as:

• A laboratory-prepared liquid blend
• Pre-mixed in 3 ml bacteriostatic water
• Sealed in a pen format for controlled handling
• Clearly labelled with known composition and volume

This removes the need for manual mixing and avoids variability introduced during preparation.

Technical Information

Product name: CagriReta
Total peptide content: 40 mg

Composition:
• Retatrutide – 30 mg
• Cagrilinitide – 10 mg

Category: Multi-pathway regulatory peptide research blend
Purity: ≥ 99% (each component)

Solvent: 3 ml bacteriostatic water
Appearance: Clear liquid
Solution colour: Clear
Format: Factory-sealed research pen

This information is provided so buyers know exactly what the product contains.

What Is Included

Each CagriReta 40 mg Research Pen includes:

• One pre-mixed CagriReta 40 mg research pen
• Individually sealed microneedles (research handling only)
• Alcohol swabs
• Printed storage and preservation notes

No instructions, dosing guidance, or research protocols are supplied.

Storage and Preservation Notes

• Store refrigerated when not in use
• Do not freeze
• Avoid direct or indirect sunlight
• Keep sealed when not being handled
• Inspect visually; the solution should remain clear

These notes are provided only to help preserve material integrity.

Related Research Products

CagriReta 40 mg is often purchased alongside other research materials such as MOTS-C, AOD-9604, SS-31, Tirzepatide, or GHK-CU to support broader comparative research.

SEMPICA HEALTHCARE does not recommend combinations or provide guidance. All decisions remain with the purchaser.

About SEMPICA HEALTHCARE

Many peptide sellers focus on selling individual vials with limited explanation and little accountability. SEMPICA HEALTHCARE focuses on clearly described, laboratory-prepared research materials supplied in a consistent and transparent format.

We provide the product.
Responsibility for its use rests entirely with you.

Important Research Use Notice

This product is supplied strictly for research and development purposes only.

It is not intended to:

• Diagnose, treat, cure, or prevent any disease
• Be used on or by humans or animals
• Be represented as a medicine, supplement, or injectable product

SEMPICA HEALTHCARE provides no guidance, plans, protocols, or advice beyond the information published here.
By purchasing, you confirm that you accept full responsibility for use, storage, handling, and regulatory compliance.

Buy CagriReta 40 mg Research Pen